MOSAIC research

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Mubadala Capital

Mubadala Capital Ventures

Bpifrance

Plug and Play

MACSF

Eight Roads Ventures

Google Ventures

Cathay Innovation

F-Prime Capital

Sanofi

Bristol-Myers Squibb

Owkin

Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025.

Our cutting-edge AI engines will maximize its probability of success by identifying the optimal indication and patient sub-population and de-risk its ongoing clinical development.

Discover our Tx and Dx pipeline at owkin.com/pipeline

What are 5 ways digital pathology is transforming healthcare?

At the Digital Pathology Place webinar, we gained insights from Dr. Aleks 🔬 Żuraw, as she shared expertise on topics spanning from clinical practice to drug development.

Read our blog https://lnkd.in/dKvChGJG

Watch the webinar https://lnkd.in/dtYNxgsn

#ASCO24 has been a whirlwind of inspiration and innovation. But don't worry, the excitement isn't over yet. Watch our round-up video as we highlight the key takeaways from this world-leading conference.

🚀 Learn how we use #AI to unlock new insights from complex datasets to power precision medicine at https://lnkd.in/exAw9qze

🇫🇷 Tomorrow, our SVP of Data Science, Eric Durand, will be speaking at the first edition of mind Health Day on ‘AI and drug discovery: how is AI accelerating research today?’ along with Arnaud Bonnaffoux, Yann Gaston-Mathe, Philippe Moingeon, and Paul Rinaudo.

Register now: https://lnkd.in/gSU-fPHn

#ASCO24 Day 3: Meriem Sefta, Owkin’s Chief Diagnostics Officer, talks about the need for cost-effective and efficient diagnostic solutions to make precision medicine a reality. To tackle this challenge, we develop #AI #diagnostics for:

🔍 Clinical trial inclusion/exclusion criteria for better patient targeting
🎯 Increasing target population for existing drugs
💊 The selection of patient subgroups with novel biomarkers for novel drugs (CDx)

Visit us at booth #30095 or book a meeting with our team to learn more about how we work with pharma to develop innovative AI diagnostics https://lnkd.in/eCemTe_Q

Our Senior Research Scientist, Maria Telenczuk, will be speaking at the Google Developer Student Clubs | University of Amsterdam on ‘Federated Learning in Biotech’ on June 5 from 5:00 to 6:30 pm CET.

Maria will discuss what federated learning is and why it's so useful for deploying AI in the healthcare world.

Register now https://lnkd.in/eKGqgFre

BioRender provides a platform for life scientists to create professional science figures in minutes.

BioRender

Pepper Flow offers a platform for managing the promotional review process in the life sciences industry.

Pepper Flow

ChemDraw provides software for drawing chemical structures and reactions.

ChemDraw

Aqemia focuses on the intersection of biology and artificial intelligence, operating within the drug discovery and development space.

Aqemia

Cradle focuses on the intersection of biology and artificial intelligence, operating within the drug discovery and development space.

Cradle

Valence is involved in the application of AI in drug discovery and development.

Valence

InstaDeep is a company that leverages AI for drug discovery and development.

InstaDeep

Owkin is an AI Biotech company that leverages artificial intelligence to advance drug discovery and development, and to create diagnostic solutions for improved patient outcomes.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Jul 3, 2024 5:08 PM	f3903cae
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 3, 2024 5:21 PM	f9880137
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 3, 2024 5:08 PM	d3108a0d
translate crunchbase fundingrounds	general
peers	general	Jul 3, 2024 5:08 PM	b9e15fa3
news basic	general	Jul 3, 2024 5:08 PM	1ef41cc6
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:OWKIN

Owkin